Nirsevimab Uptake in a Pediatric Primary Care Network During the 2023-2024 RSV Season
Open Access
- 1 July 2025
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (7) , e2520440
Abstract
This cohort study characterizes nirsevimab uptake among infants who did and did not receive the respiratory syncytial virus (RSV) vaccine during the 2023 to 2024 RSV season.Keywords
This publication has 6 references indexed in Scilit:
- Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024JAMA Pediatrics, 2025
- Successful Implementation of Nirsevimab and Factors Influencing Uptake in Neonatal CareHospital Pediatrics, 2025
- Uptake of Maternal RSV Vaccination and Infant Nirsevimab Among Infants Born October 2023 to March 2024JAMA Network Open, 2025
- Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months — United States, April 2024MMWR. Morbidity and Mortality Weekly Report, 2024
- Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)Archives of Disease in Childhood, 2024
- Disparities in the Availability and Acceptance of Nirsevimab in MassachusettsPediatrics, 2024